Resurge Therapeutics Inc.

Shahram Shawn Gholami

Olof Mikael Trollsas

John J Stankus

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Apparatus for treating Benign Prostatic Hyperplasia

Treatments for benign prostatic hyperplasia

Treating benign prostatic hyperplasia

A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.

Growing community of inventors

Monte Sereno, CA, United States of America

Shahram Shawn Gholami